PD 157945
Latest Information Update: 19 Oct 2000
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for HIV infections treatment in USA (Unknown route)
- 21 Jul 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 13 Nov 1995 New profile